Literature DB >> 9018771

Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures.

G M Van Dam1, C H Gips.   

Abstract

BACKGROUND/
METHODS: In 1979 death rate registration for primary biliary cirrhosis (PBC) became available in The Netherlands. In the 14-year period 1979-92, 417 persons died of and 179 with PBC. We investigated secondary causes of death using standardized mortality ratios (SMR) (1.0 as reference, P < 0.001 regarded as significant).
RESULTS: Median age was 70-74 (35 to > 85) years. Secondary causes of death originated from the circulatory, digestive, and respiratory tracts and malignancies. Younger persons (< 60 years), dying of PBC, more often died with "toxicity related to immunosuppression' than older persons (P < 0.01). Younger persons (< 60) dying with PBC, more often died of hepatocellular carcinoma (HCC) than older ones (P < 0.05). In patients with PBC the frequency of HCC (SMR, 25.5; P < 0.0001) and diseases of the musculoskeletal system/connective tissue (SMR, 5.1; P < 0.0001) was higher than in the general population. Malignancies in general (SMR, 0.7), pancreatic carcinoma (SMR, 2.5), breast cancer (SMR, 0.1) and diseases of the circulatory system (SMR, 0.8) differed but not significantly (P < 0.05 - < 0.01). No difference existed in the localization of malignancies in patients dying of as compared with those dying with PBC.
CONCLUSIONS: Deaths occurred predominantly in the older age classes, with an age-related difference in some associated disorders. Patients with PBC showed an increased risk of HCC and diseases of the musculoskeletal system. Similar studies from different countries are needed.

Entities:  

Mesh:

Year:  1997        PMID: 9018771     DOI: 10.3109/00365529709025067

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  15 in total

1.  Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis.

Authors:  M Allocca; A Crosignani; A Gritti; G Ghilardi; D Gobatti; D Caruso; M Zuin; M Podda; P M Battezzati
Journal:  Gut       Date:  2006-04-21       Impact factor: 23.059

2.  Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort.

Authors:  M I Prince; A Chetwynd; W L Craig; J V Metcalf; O F W James
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  Assessment of metabolic syndrome in patients with primary biliary cirrhosis.

Authors:  Tamara Alempijevic; Aleksandra Sokic-Milutinovic; Aleksandra Pavlovic Markovic; Rada Jesic-Vukicevic; Biljana Milicic; Djuro Macut; Dragan Popovic; Dragan Tomic
Journal:  Wien Klin Wochenschr       Date:  2012-04-25       Impact factor: 1.704

4.  Hyperlipidemia in Chronic Cholestatic Liver Disease.

Authors:  Matteo Longo; Andrea Crosignani; Mauro Podda
Journal:  Curr Treat Options Gastroenterol       Date:  2001-04

5.  Asymptomatic primary biliary cirrhosis is not associated with increased frequency of cardiovascular disease.

Authors:  Iliana Doycheva; Chaoru Chen; Jen-Jung Pan; Cynthia Levy
Journal:  World J Hepatol       Date:  2011-04-27

6.  Cancer risk in primary biliary cirrhosis: a study in northern England.

Authors:  D Howel; J V Metcalf; J Gray; W L Newman; D E Jones; O F James
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

7.  Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States.

Authors:  Marion G Peters; Adrian M Di Bisceglie; Kris V Kowdley; Nancy L Flye; Velimir A Luketic; Santiago J Munoz; Guadalupe Garcia-Tsao; Thomas D Boyer; John R Lake; Maurizio Bonacini; Burton Combes
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

8.  Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis.

Authors:  M Longo; A Crosignani; P M Battezzati; C Squarcia Giussani; P Invernizzi; M Zuin; M Podda
Journal:  Gut       Date:  2002-08       Impact factor: 23.059

9.  Rosiglitazone alleviates intrahepatic cholestasis induced by α-naphthylisothiocyanate in mice: The role of circulating 15-deoxy-Δ12,14 -PGJ2 and Nogo.

Authors:  Shuang Zhang; Miao Yu; Fangling Guo; Xiaoxiao Yang; Yuanli Chen; Chuanrui Ma; Qi Li; Zhuo Wei; Xiaoju Li; Hua Wang; Huaqing Hu; Yujue Zhang; Derun Kong; Qing Robert Miao; Wenquan Hu; David P Hajjar; Yan Zhu; Jihong Han; Yajun Duan
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

10.  Incidence, mortality, and predictive factors of hepatocellular carcinoma in primary biliary cirrhosis.

Authors:  Kenichi Hosonuma; Ken Sato; Masatoshi Yanagisawa; Satoru Kakizaki; Hitoshi Takagi; Junko Hirato; Masatomo Mori
Journal:  Gastroenterol Res Pract       Date:  2013-02-25       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.